Clinical trials: Asthma/ COPD
Pulmonary Disease, Chronic Obstructive, Asthma
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of Berodual delivered via the…
- Trial name
- NCT00153075
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Asthma
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
This is a comparative bioavailability study to compare the pharmacokinetics and pharmacodynamic effects of Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler in…
- Trial name
- NCT01494610
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference…
- Trial name
- NCT01634620
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Aerocrine AB
Asthma
WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Work Package 2 and Workgroup 1.
- Trial name
- NCT01636726
- Testing
- Inhaled LABA use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Asthma
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD.
- Conditions
- Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00157339
- Testing
- Human Insulin Inhalation Powder, injected insulin
- Where
- 101 sites in United States, Argentina and 14 more
- Volunteers
- 299 people
- Sponsor
- Eli Lilly and Company
Asthma, Chronic Obstructive Pulmonary Disease
Interpreting Respiratory Oscillometry in Adult Asthma and COPD: a Delphi Study
This is an international Delphi study to consolidate expert consensus on the use of respiratory oscillometry in the management of adult patients with asthma or chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT06313372
- Testing
- Respiratory oscillometry
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Scius Healthcare Solutions Pty Ltd
Chronic Obstructive Pulmonary Disease (COPD), Asthma
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety…
- Trial name
- Breztri rPMS (NCT07570394)
- Where
- 10 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Asthma
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
AZD7594 is a non steroidal, potent and selective modulator of the glucocorticoid receptor (GR) under development for once daily inhaled treatment of chronic obstructive pulmonary disease (COPD) and asthma.
- Trial name
- NCT02967159
- Testing
- Abediterol, AZD7594, AZD7594/abediterol
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, COPD
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
The objective of this pivotal study is to evaluate the relative bioavailability of SYN010 HFA Inhaler and Symbicort 160/4.5μg in healthy volunteers without charcoal block.
- Trial name
- NCT04494321
- Testing
- Budesonide, Formoterol
- Where
- Taiwan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Intech Biopharm Ltd.
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Asthma, COPD
The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients
A Multi-centre, retrospective study describing the impact of PCCM standardized implementation on healthcare management among Asthma or COPD or Asthma-COPD overlap patients in Tianjin city of China, using real world electronic…
- Conditions
- Asthma, COPD, Asthma-COPD Overlap
- Trial name
- PCCM-IMPACTS (NCT04905420)
- Where
- China
- Volunteers
- 288,538 people
- Sponsor
- AstraZeneca
Asthma
GSK2190915A - Bioavailability Study
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that reduces inflammation in cells. This study will evaluate three capsule and two tablet formulations to select the optimal formulation for further…
- Trial name
- NCT02224521
- Testing
- GSK2190915 Solution., GSK2190915 Granule Capsule (A), GSK2190915 Semi-solid Lipid Capsule (B)
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma Bronchiale, Bronchiectasis
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
- Conditions
- Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06820749
- Testing
- HSK31858
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Asthma, COPD
An Evaluation of 9MW1911 Injection in Healthy Subjects
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05803902
- Testing
- Experimental drug 9MW1911
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Healthy Participants
A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers
The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.
- Trial name
- NCT06304961
- Testing
- Tozorakimab
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone Easyhaler to achieve and maintain asthma or COPD control.
- Trial name
- SUNNY (NCT03755544)
- Where
- Germany
- Volunteers
- 231 people
- Sponsor
- Orion Corporation, Orion Pharma
Patient Satisfaction
Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
The main aim of the study is to investigate patient satisfaction in the treatment of asthma and COPD with the new device of DuoResp® Spiromax® and patient preference.
- Trial name
- NCT02384577
- Testing
- Budesonide, Formoterol Fumarate Dihydrate
- Where
- Germany
- Volunteers
- 4,034 people
- Sponsor
- Teva Pharma GmbH
Asthma COPD
Clinical and Medico-economic Validation of the HEPHAI Solution.
In a context where the use of inhalation devices for respiratory medications is associated with a high frequency of critical errors, our primary hypothesis is that the use of the HEPHAÏ solution reduces this frequency compared to…
- Trial name
- VAL-HEPHAI (NCT06099145)
- Testing
- Hephaï
- Where
- 5 sites in France
- Volunteers
- 238 people
- Sponsor
- Hephai
Sleep Apnea, Asthma
Sleepiz One+ vs. Capnography and Electrocardiography
Respiratory Rate (RR) and heart rate (HR) are vital signs crucial for assessing a patient's overall health, providing insights into various conditions and stressors.
- Conditions
- Sleep Apnea, Asthma, COPD, Hypertension
- Trial name
- NCT06569940
- Testing
- Sleepiz One+
- Where
- Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sleepiz AG
Asthma
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
This study is the second Phase-II trial analyzing efficacy outcomes of PBF-680 in asthmatic subjects, following the supportive data from the proof-of-concept trial on the effect of PBF-680 on airway hyperresponsiveness to…
- Trial name
- NCT02635945
- Testing
- PBF-680
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Palobiofarma SL